Seasonal Influenza Therapeutics in Asia-Pacific Markets to 2022 – Growth Driven by Rising Elderly Population, Growing Awareness and Launch of Quadrivalent Therapies

US$ 4995

Influenza, often referred to as the flu, is an acute infection caused by one of the three closely related viruses, designated as influenza Type A, B, and C. The infection’s rapid onset and potential for high morbidity and mortality, particularly in high-risk patient populations such as the elderly and young children, make prompt and effective treatment with antiviral medication very difficult.

02-03 2017   Pages: 108

Frontier Pharma: Melanoma Therapeutics – Cytokine and Multiple Targeted Small Molecules and mAbs Dominate Pipeline and First-in-Class Innovation

US$ 6995

Melanoma is a type of cancer that begins in the melanocytes, often in moles or other pigmented tissues. It most commonly affects the skin, as cutaneous melanoma; however it can also affect other pigmented tissues, such as the eye or intestines, as extracutaneous melanoma. It is the deadliest form of skin cancer and remains one of the most aggressive and treatment-resistant human cancers.

02-03 2017   Pages: 81

United States Influenza Vaccine Market, Vaccination Analysis, Distribution, Production, Pipeline Insights, Clinical Trials, Deals Type, Regulatory, Price Trends, Competitive Strategies and Forecast,2016 to 2022

US$ 1000

Market growth can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against influenza vaccine and introduction of quadrivalent influenza vaccine.

12-19 2016   Pages: 122

Diabetes & Obesity Drug Development Pipeline Review, 2016

US$ 3995

The diabetes and obesity disease cluster is currently dominated by therapeutics indicated for type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM), and the majority of the pipeline, in terms of both quantity and quality of products, is attributable to these indications. While products indicated for obesity do not currently have a large market presence, there are a large number of these products in the pipeline, with the majority in early stages of development.

11-22 2016   Pages: 560

Ophthalmology Drug Development Pipeline Review, 2016

US$ 3995

Ophthalmology disorders are associated with the eyes and visual system. If left untreated, serious long-term co-morbidities such as diabetes, and particularly blindness, can arise.

11-22 2016   Pages: 633

Global Cardiovascular Disease Market to 2022 – Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth

US$ 4995

“Global Cardiovascular Disease Market to 2022 – Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth

11-14 2016   Pages: 192

Frontier Pharma: Ophthalmology Therapeutics – Advancements in Disease Understanding Pave Way for Increasingly Diverse Therapeutic Options, with Age-Related Macular Degeneration and Glaucoma Leading the Way

US$ 6995

“Frontier Pharma: Ophthalmology Therapeutics – Advancements in Disease Understanding Pave Way for Increasingly Diverse Therapeutic Options, with Age-Related Macular Degeneration and Glaucoma Leading the Way

11-14 2016   Pages: 70

Global Gastrointestinal Drug Market to 2022 – Pipeline Characterized by Emerging Biologic Therapies, While TNF Inhibitors and PPIs Continue to Dominate Therapy Landscape

US$ 4995

“Global Gastrointestinal Drug Market to 2022 – Pipeline Characterized by Emerging Biologic Therapies, While TNF Inhibitors and PPIs Continue to Dominate Therapy Landscape

11-09 2016   Pages: 161

Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022 – Growth Driven by Increasing Prevalence and Launch of Targeted Therapies

US$ 4995

“Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022 – Growth Driven by Increasing Prevalence and Launch of Targeted Therapies

11-09 2016   Pages: 112

Frontier Pharma: Glioblastoma Multiforme – Cancer Immunotherapies Dominate First-in-Class Product Innovation

US$ 6995

“Frontier Pharma: Glioblastoma Multiforme – Cancer Immunotherapies Dominate First-in-Class Product Innovation

11-09 2016   Pages: 73
Contact With Us
Join templatemonster at google+
Customized Research
Request Sample